These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 33371456)

  • 41. Harnessing NK Cells for Cancer Treatment.
    Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E
    Front Immunol; 2019; 10():2836. PubMed ID: 31867006
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future?
    Liu F; Miao X; Han L; Song X
    Front Oncol; 2024; 14():1390006. PubMed ID: 38863635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy.
    Wu X; Matosevic S
    Mol Ther Oncolytics; 2022 Dec; 27():224-238. PubMed ID: 36420307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies.
    Lu H; Zhao X; Li Z; Hu Y; Wang H
    Front Oncol; 2021; 11():720501. PubMed ID: 34422667
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles.
    Kim KS; Kim DH; Kim DH
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33918941
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NK Cell Metabolism and Tumor Microenvironment.
    Terrén I; Orrantia A; Vitallé J; Zenarruzabeitia O; Borrego F
    Front Immunol; 2019; 10():2278. PubMed ID: 31616440
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
    Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
    J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
    Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
    Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
    Hu W; Wang G; Huang D; Sui M; Xu Y
    Front Immunol; 2019; 10():1205. PubMed ID: 31214177
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chimeric Antigen Receptors for the Tumour Microenvironment.
    Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
    Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.
    Burga RA; Yvon E; Chorvinsky E; Fernandes R; Cruz CRY; Bollard CM
    Clin Cancer Res; 2019 Jul; 25(14):4400-4412. PubMed ID: 31010834
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Natural killer cells: of-the-shelf cytotherapy for cancer immunosurveillance.
    Zhang L; Liu M; Yang S; Wang J; Feng X; Han Z
    Am J Cancer Res; 2021; 11(4):1770-1791. PubMed ID: 33948388
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors.
    Portillo AL; Hogg R; Poznanski SM; Rojas EA; Cashell NJ; Hammill JA; Chew MV; Shenouda MM; Ritchie TM; Cao QT; Hirota JA; Dhesy-Thind S; Bramson JL; Ashkar AA
    iScience; 2021 Jun; 24(6):102619. PubMed ID: 34159300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NK cell surveillance of hematological malignancies. Therapeutic implications and regulation by chemokine receptors.
    Tomaipitinca L; Russo E; Bernardini G
    Mol Aspects Med; 2021 Aug; 80():100968. PubMed ID: 34045078
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NK cells and solid tumors: therapeutic potential and persisting obstacles.
    Tong L; Jiménez-Cortegana C; Tay AHM; Wickström S; Galluzzi L; Lundqvist A
    Mol Cancer; 2022 Nov; 21(1):206. PubMed ID: 36319998
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
    Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
    Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CAR-T in solid tumors: Blazing a new trail through the brambles.
    Guo F; Cui J
    Life Sci; 2020 Nov; 260():118300. PubMed ID: 32827541
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.